Semaglutide-based medications, Ozempic and Wegovy, are used respectively for the treatment of Type 2 diabetes and weight loss.
Ozempic helps control blood sugar levels in adults with Type 2 diabetes by activating GLP-1 receptors. It enhances insulin secretion and reduces glucagon secretion from the liver primarily.
Wegovy is prescribed for chronic weight management in adults and children over 12 years of age who are obese or have weight-related medical problems. It works by mimicking GLP-1, reducing appetite and food intake. The FDA also recently approved Wegovy to help decrease cardiovascular risks in patients with heart disease, obesity, and overweight (FDA, 2024).
The insurance coverage for these medications varies depending on the specific health insurance provider and individual plans (Novo Nordisk, 2022). Medicare does not usually cover weight management medications, but some Medicare Advantage plans may offer coverage (CMS, 2023). Additionally, Medicare recently announced opening up Wegovy coverage for heart disease patients (Reuters, 2024). Commercial insurance and employer-provided plans also vary, often based on the inclusion of obesity treatments in prescription benefits.
Health insurance companies like Blue Cross Blue Shield and Aetna cover semaglutide based on the specifics of the individual's health plan (BCBS, 2023; Aetna, 2023). These insurers typically require evidence of previous weight management efforts, such as consultations with nutritionists or participation in weight loss programs, before approving coverage for Wegovy for weight loss. The Department of Veterans Affairs requires trials of other weight management strategies before considering Wegovy, evaluating each case on its own merits (U.S. Department of Veterans Affairs, 2023). Because Ozempic is primarily indicated for treating type II diabetes, it is more likely to be covered by insurance plans than Wegovy. Additionally, Ozempic has been on the market longer and may be more established in insurance formularies.
The out-of-pocket costs for Wegovy and Ozempic can be significant if not covered by insurance. Wegovy's list price is approximately $1,349 per month, but with insurance, it can be significantly reduced (GoodRx, 2024). Ozempic's pricing structure is similar, with costs varying based on the coverage provided by employer-sponsored plans or Medicare Advantage.
Both Wegovy and Ozempic can have side effects, some of which can be serious. Possible side effects may include nausea, diarrhea, vomiting, constipation, and abdominal pain. Both medications have also been associated with more severe risks, such as pancreatitis (Novo Nordisk, 2022).
Experts suggest that, like many chronic medications, such as those used for hypertension, semaglutide may need to be taken long-term (Healthline, 2023; Nature, 2024). Therefore, once patients start on medications like Wegovy or Ozempic, they may need to continue indefinitely to maintain their health benefits, particularly without alternative treatments or significant lifestyle changes that address the underlying conditions.
Additionally, when discontinued, both Wegovy and Ozempic have shown a tendency for patients to regain some of the weight they initially lost (Rubino et al., 2021). This pattern is evident in the STEP 1 trial extension data, where participants who had lost an average of 17% of their body weight on semaglutide regained around two-thirds of their lost weight within a year after stopping the medication (Wilding et al., 2022). This suggests that, like many chronic condition treatments, long-term or indefinite use of these medications might be necessary to maintain their benefits. Significant weight regain after discontinuation of GLP-1 receptor agonists like semaglutide indicates the importance of considering these as part of a long-term management strategy for weight and related metabolic conditions.
When considering treatment with semaglutide, it is important to talk with your healthcare provider to establish a treatment plan and verify insurance coverage details. Understanding potential out-of-pocket costs and pre-authorization requirements is important for managing expectations and ensuring treatment accessibility.
References:
• FDA. (2024). “FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.” Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
• Novo Nordisk. (2022). "Wegovy and Ozempic: Indications and Usage." Retrieved from https://www.novonordisk.com
• Centers for Medicare & Medicaid Services (CMS). (2023). "Medicare Coverage Database." Retrieved from https://www.cms.gov
• Reuters. (2024). “Wegovy to be covered by US Medicare for heart disease patients: Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-be-covered-by-us-medicare-heart-disease-patients-2024-03-21/
• Blue Cross Blue Shield (BCBS). (2023). "Medical Policies." Retrieved from https://www.bcbs.com
• Aetna. (2023). "Clinical Policy Bulletins." Retrieved from https://www.aetna.com
• U.S. Department of Veterans Affairs. (2023). "Pharmaceutical Guidelines for Weight Management." Retrieved from https://www.va.gov
• GoodRx. (2024). "Wegovy and Ozempic Pricing Information." Retrieved from https://www.goodrx.com
• Healthline. (2023). "Long-Term Use of Diabetes Medications." Retrieved from https://www.healthline.com
• Nature. (2024). Obesity drugs aren't always forever. What happens when you quit? Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off them. Retrieved from https://www.nature.com/articles/d41586-024-01091-8
• Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, 325(14), 1414–1425. DOI: 10.1001/jama.2021.3224.
• Wilding, JPH, Batterham, RL, Davies, M., Van Gaal, LF, Kandler, K., Konakli, K., et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes Obes Metab, 24(8), 1553–1564. DOI: 10.1111/dom.14725